• 3. Special items
• 4. Sales
• 5. Cost of sales
• 6. Cost of materials
• 7. Personnel expenses
• 8. Selling, general and administrative expenses
• 9. Investment gain
• 10. Net interest
• 11. Other financial result
• 12. Taxes
• 13. Earnings per share

9. Investment gain

Fresenius Medical Care’s acquisition of the remaining 51% stake in Renal Advantage Partners, LLC, in addition to its 49% equity investment held previously, represents a business combination achieved in stages in the course of the acquisition of Liberty Dialysis Holdings, Inc. The previous equity investment was measured at its fair value at the date of the acquisition of Liberty Dialysis Holdings, Inc. by Fresenius Medical Care. The resultant non-taxable income of US$140 million (€109 million) is presented in the separate line item investment gain in the consolidated statement of income.